Sign In
Buy APVO
$5.02
-0.0200 (-0.397%)
At Close: Jun 03, 2026
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
08:05pm, Monday, 16'th Sep 2024
SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
01:06pm, Thursday, 15'th Aug 2024
Aptevo Therapeutics (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
08:05am, Tuesday, 13'th Aug 2024
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data report
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
08:05am, Thursday, 08'th Aug 2024
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprie
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
04:20pm, Monday, 01'st Jul 2024
SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprieta
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
09:20am, Friday, 28'th Jun 2024
SEATTLE, WA / ACCESSWIRE / June 28, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its propriet
Aptevo Participating in the BIO International Convention
08:05am, Monday, 03'rd Jun 2024
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprieta
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
09:21am, Tuesday, 28'th May 2024
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Se
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
08:05am, Tuesday, 14'th May 2024
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologies SEATTLE, WA / ACCESSWIRE / May 14, 2024 /
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
08:05am, Wednesday, 08'th May 2024
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease a
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
07:36am, Wednesday, 24'th Apr 2024
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Groupon (GRPN), Aptevo Therapeutics (APVO), NewJersey Resources (NJR), American Water Works (AWK)
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
01:51pm, Tuesday, 16'th Apr 2024
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
04:05pm, Monday, 15'th Apr 2024
SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprie
Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?
08:15am, Thursday, 11'th Apr 2024
Aptevo Therapeutics (NASDAQ: APVO ) stock is falling on Thursday after the clinical-stage biotechnology company priced a public offering for its shares. That public offering has Aptevo Therapeutics s
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
08:00am, Thursday, 11'th Apr 2024
SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprie
